In New Study Marijuana Reduced Epileptic Seizures by 86% Among All Participants

Whole-plant marijuana oil reduced seizures by 86% among all participants of a new study published by the scientific journal BMJ Paediatrics Open.

The study, titled Medical cannabis for severe treatment resistant epilepsy in children: a case-series of 10 patients, was also epublished by the U.S. National Institute of Health. The objective of the study, according to its abstract, is “To report the findings of a case-series of 10 children suffering with intractable epilepsies in the UK to determine the feasibility for using whole-plant cannabis medicines to treat seizures in children.”

The study was conducted “retrospectively through collecting clinical data from caretakers and clinicians on study outcome variables.” Participants were recruited through the MedCann Support and End our Pain charity groups which are patient representative groups that support children who are using medical cannabis to treat their epilepsies. “Medicines were prescribed to patients by clinicians in both National Health Service and private medical practices.” Follow-up calls “were conducted throughout the period January 2021 to May 2021 to keep data recorded up to date.”

The participants were “Ten children, 18 years old or under, with intractable epilepsies were recruited from two charities. There were no limitations on diagnosis, sex or ethnic origin.”

For the study participants were treated with a range of whole-plant medical cannabis oils. Individual dosing regimens were determined by clinicians.

Researchers found that “Seizure frequency across all 10 participants reduced by 86% with no significant adverse events. Participants reduced use of antiepileptic drugs from an average of seven to one following treatment with medical cannabis. We also noted significant financial costs of £874 per month to obtain these medicines through private prescriptions.”

The study  concludes by stating that “This study establishes the feasibility of whole-plant medical cannabis as an effective and well-tolerated medicine for reducing seizure frequency in children suffering with intractable epilepsies. These findings justify the potential value of further research into the reported therapeutic benefit of whole-plant medicinal cannabis products.”

Below is the study’s full abstract:

Abstract

Objectives To report the findings of a case-series of 10 children suffering with intractable epilepsies in the UK to determine the feasibility for using whole-plant cannabis medicines to treat seizures in children.

Setting This study was conducted retrospectively through collecting clinical data from caretakers and clinicians on study outcome variables. Participants were recruited through the MedCann Support and End our Pain charity groups which are patient representative groups that support children who are using medical cannabis to treat their epilepsies. Medicines were prescribed to patients by clinicians in both National Health Service and private medical practices. Follow-up calls were conducted throughout the period January 2021 to May 2021 to keep data recorded up to date.

Participants Ten children, 18 years old or under, with intractable epilepsies were recruited from two charities. There were no limitations on diagnosis, sex or ethnic origin.

Interventions Participants were treated with a range of whole-plant medical cannabis oils. Individual dosing regimens were determined by clinicians.

Primary outcome measure The primary outcome measure was seizure frequency.

Results Seizure frequency across all 10 participants reduced by 86% with no significant adverse events. Participants reduced use of antiepileptic drugs from an average of seven to one following treatment with medical cannabis. We also noted significant financial costs of £874 per month to obtain these medicines through private prescriptions.

Conclusions This study establishes the feasibility of whole-plant medical cannabis as an effective and well-tolerated medicine for reducing seizure frequency in children suffering with intractable epilepsies. These findings justify the potential value of further research into the reported therapeutic benefit of whole-plant medicinal cannabis products.

1 comment

    • Obb on December 22, 2021 at 11:39 pm
    • Reply

    interesting stuff

Leave a Reply

Your email address will not be published.